
## **Richard N Fedorak**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5004982/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis. Inflammatory Bowel Diseases, 2020, 26, 1909-1916.	0.9	34
2	An overview of clinical decision support systems: benefits, risks, and strategies for success. Npj Digital Medicine, 2020, 3, 17.	5.7	992
3	Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization. Crohn's & Colitis 360, 2020, 2, .	0.5	8
4	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. Frontiers in Medicine, 2019, 6, 170.	1.2	6
5	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129
6	IBDoc Canadian User Performance Evaluation. Inflammatory Bowel Diseases, 2019, 25, 1107-1114.	0.9	8
7	Early Initiation of Tumor Necrosis Factor Antagonist–Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. Clinical Gastroenterology and Hepatology, 2019, 17, 1515-1524.e4.	2.4	14
8	Heterogeneity in Definitions of Efficacy and Safety EndpointsÂforÂClinical Trials of Crohn's Disease: AÂSystematicÂReview. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	2.4	41
9	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	2.4	44
10	Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. Frontiers in Immunology, 2018, 9, 2211.	2.2	22
11	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. Journal of the Canadian Association of Gastroenterology, 2018, 1, 115-123.	0.1	34
12	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open, 2017, 7, e016146.	0.8	35
13	Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. Open Forum Infectious Diseases, 2017, 4, ofw275.	0.4	62
14	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. World Journal of Gastroenterology, 2017, 23, 3890.	1.4	28
15	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-11.	0.8	6
16	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-9.	0.8	20
17	Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. American Journal of Gastroenterology, 2016, 111, 691-704.	0.2	56
18	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. Digestive Diseases and Sciences, 2016, 61, 1895-1902.	1.1	9

**RICHARD N FEDORAK** 

#	Article	IF	CITATIONS
19	Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study. Metabolomics, 2016, 12, 1.	1.4	6
20	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes. Inflammatory Bowel Diseases, 2016, 22, 870-879.	0.9	63
21	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. Gastroenterology, 2016, 150, e1-e2.	0.6	4
22	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. Digestive Diseases, 2016, 34, 112-121.	0.8	7
23	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 928-935.e2.	2.4	181
24	Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World Journal of Gastroenterology, 2014, 20, 4934.	1.4	95
25	Development and Validation of a Highly Sensitive Urine-Based Test to Identify Patients with Colonic Adenomatous Polyps. Clinical and Translational Gastroenterology, 2014, 5, e54.	1.3	36
26	Real-life Treatment Paradigms Show Infliximab Is Cost-effective forÂManagement of Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1871-1878.e8.	2.4	11
27	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. Journal of Crohn's and Colitis, 2014, 8, 1454-1463.	0.6	43
28	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
29	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naĀīve to anti-TNF therapy: An indirect treatment comparison meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 571-581.	0.6	66
30	Distance management of inflammatory bowel disease: Systematic review and meta-analysis. World Journal of Gastroenterology, 2014, 20, 829.	1.4	64
31	Canadian Digestive Health Foundation Public Impact Series 3: Irritable Bowel Syndrome in Canada. Incidence, Prevalence, and Direct and Indirect Economic Impact. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 252-256.	1.8	14
32	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut, 2011, 60, 780-787.	6.1	750
33	A Randomized Trial of Topical Anesthesia Comparing Lidocaine Versus Lidocaine Plus Xylometazoline for Unsedated Transnasal Upper Gastrointestinal Endoscopy. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 317-321.	1.8	16
34	Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 651-655.	1.8	21
35	Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal Reflux Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 431-434.	1.8	31
36	Effect ofLactobacillus plantarum299v treatment in an animal model of irritable bowel syndrome. Microbial Ecology in Health and Disease, 2009, 21, 33-37.	3.8	6

RICHARD N FEDORAK

#	Article	IF	CITATIONS
37	VSL#3 Probiotic Upregulates Intestinal Mucosal Alkaline Sphingomyelinase and Reduces Inflammation. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 237-242.	1.8	69
38	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Advanced Drug Delivery Reviews, 2005, 57, 303-316.	6.6	82
39	Probiotics and the Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 286-299.	0.9	155
40	ls it time to re-classify Crohn's disease?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 99-106.	1.0	11
41	Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 2004, 20, 146-155.	1.0	108
42	Trace Element Contamination of Total Parenteral Nutrition. 1. Contribution of Component Solutions. Journal of Parenteral and Enteral Nutrition, 1999, 23, 222-227.	1.3	81
43	Antigenic Mimicry BetweenHelicobacter pyloriand Gastric Mucosa: Failure to Implicate Heatâ€Shock Protein Hsp60 Using Immunoelectron Microscopy. Helicobacter, 1999, 4, 148-153.	1.6	10
44	Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine. American Journal of Physiology - Renal Physiology, 1998, 274, G96-G102.	1.6	74
45	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. , 1997, 18, 681-695.		8
46	Osteoporosis of Crohn's Disease: A Critical Review. Canadian Journal of Gastroenterology & Hepatology, 1996, 10, 317-321.	1.8	0
47	Clinical Aspects of Trace Elements: Zinc in Human Nutrition - Assessment of Zinc Status. Canadian Journal of Gastroenterology & Hepatology, 1996, 10, 37-42.	1.8	11
48	Increased permeability occurs in rat ileum following induction of pancolitis. Digestive Diseases and Sciences, 1996, 41, 405-411.	1.1	13
49	Clinical Aspects of Trace Elements: Zinc in Human Nutrition – Zinc Requirements. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 368-372.	1.8	Ο
50	A Profile of Patients on ASA or NSAIDs Hospitalized with Gastrointestinal Perforations. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 387-392.	1.8	1
51	Vanadate reduces sodium-dependent glucose transport and increases glycolytic activity in LLC-PK1 epithelia. Journal of Cellular Physiology, 1994, 158, 459-466.	2.0	4
52	Acetic acid-induced colitis results in bystander ileal injury. Agents and Actions, 1993, 38, 76-84.	0.7	10
53	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. Digestive Diseases and Sciences, 1992, 37, 205-214.	1.1	79
54	Glutamine and Its Effects on the Intestine. Canadian Journal of Gastroenterology & Hepatology, 1991, 5, 94-102.	1.8	0

#	Article	IF	CITATIONS
55	Short Bowel Syndrome. , 0, , 1295-1321.		Ο
56	Short Bowel Syndrome. , 0, , 340-357.		1